C4 Therapeutics to Present Data from the Ongoing Phase 1/2 …
11 hours ago · About C4 Therapeutics. C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a ...
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 …
11 hours ago · C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage ...
Investor Relations – C4 Therapeutics, Inc.
Oct 15, 2024 · C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 …
Dec 12, 2023 · Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma Activity and Immunomodulatory Effects to Support CFT7455 in Combination with Novel Multiple Myeloma Agents and as a Monotherapy Maintenance Option.
C4 Therapeutics Announces License and Research Collaboration …
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that it has entered into an exclusive ...
C4 Therapeutics Announces 2024 Priorities and Extended Cash …
Key 2024 priorities include advancing the CFT7455 and CFT1946 clinical programs to value-inflection milestones, supporting CFT8919 Phase 1 development in China by partner Betta Pharmaceuticals,...
C4 Therapeutics Announces License and Research Collaboration …
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Announces License and Research - GlobeNewswire
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
2024-11-05 | C4 Therapeutics to Present Data from the
1 day ago · C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET) WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ...
C4 Therapeutics to Present Data from the Ongoing Phase 1/2
11 hours ago · C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of ...
- Some results have been removed